September 25, 2017
Via EDGAR Correspondence
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Ms. Irene Paik
Re: Ohr Pharmaceutical, Inc.
Registration Statement on Form S-3
September 15, 2017
File No. 333-220487
Dear Ms. Paik:
Pursuant to Rule 461 of the Securities Act of 1933, as amended, the undersigned registrant under the above-referenced registration statement hereby requests acceleration of the effective date of the registration statement to September 27, 2017, at 4:00 p.m., New York time, or as soon as practicable thereafter. Please notify our outside counsel, Joseph Walsh, Esq., by phone at (212) 704-6030, by fax at (212) 704-5919, or by email at firstname.lastname@example.org of the date and time that the registration statement has been declared effective.
|Very truly yours,|
|Ohr Pharmaceutical, Inc.|
|By:||/s/ Sam Backenroth|
|Name: Sam Backenroth|
|Title: Chief Financial Officer|
|cc:||Dr. Jason Slakter, Chief Executive Officer, Ohr Pharmaceutical, Inc.|
|Aurora Cassirer, Esq. Troutman Sanders, LLP|
|Joseph Walsh, Esq., Troutman Sanders, LLP|